Clinical Trial Update: First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector [Phase 1]

View source ↗

Summary

The first-in-human Phase 1 study of NG-641, a tumor-selective transgene-expressing adenoviral vector from Akamis Bio, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Carcinoma

Drugs mentioned

• NG-641

Snippet

Sponsor: Akamis Bio | Conditions: Metastatic Cancer, Epithelial Tumor | Phase 1 | Status: COMPLETED